BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 27, 2021
View Archived Issues
Health Canada approves clinical trials of AT-1501 in kidney transplantation
Read More
Interim update on first-in-human study of SB-11285 in solid tumors
Read More
PolarityTE submits IND for SkinTE in chronic cutaneous ulcers
Read More
Yeast study reveals potential cancer therapy approach
Read More
Japan Tobacco divulges new NLRP3 inflammasome inhibitors
Read More
Beijing Scitech-Mq Pharmaceuticals identifies new FGFR4 inhibitors
Read More
New DGAT-2 inhibitors discovered at LG Chem
Read More
Ophirex initiates phase II study of varespladib in severe COVID-19
Read More
Jiangsu Simcere Pharmaceutical R&D describes TGF-beta receptor type-1 inhibitors
Read More
Cerecor reports initial phase Ib data on CERC-002 in moderate to severe Crohn's disease
Read More
Leo Pharma begins phase IIa study of LEO-138559 for moderate to severe atopic dermatitis
Read More
XWPharma starts first-in-human study of XW-10508
Read More
Inozyme opens enrollment in phase I/II study of INZ-701 for ENPP1 deficiency
Read More
Responses seen with personalized neoantigen peptide vaccine in NSCLC patients with EGFR mutations
Read More
Enrollment opens in phase I study of BI-1569912 for major depressive disorder
Read More
Inhalable human ACE2-containing nanocatchers may protect host cells from SARS-CoV-2 infection
Read More
First-in-human safety and PK data reported for pirepemat
Read More
Xenon Pharmaceuticals targets Nav1.5 with aryl sulfonamide inhibitors
Read More
Grunenthal begins phase I trial of glucocorticoid receptor modulator
Read More